Welcome to our dedicated page for PRVB news (Ticker: PRVB), a resource for investors and traders seeking the latest updates and insights on PRVB stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PRVB's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PRVB's position in the market.
Provention Bio (Nasdaq: PRVB) has appointed Dr. Jan Hillson as Senior Vice President of Clinical Development, enhancing its leadership in autoimmune disease therapies. Dr. Hillson, with over 20 years of experience in clinical research, will lead the PREVAIL-2 study for PRV-3279, targeting systemic lupus erythematosus. Her previous roles include Senior Vice President at Alpine Immune Sciences and ChemoCentryx. Provention's pipeline includes candidates aimed at treating autoimmune conditions, emphasizing its commitment to addressing significant unmet medical needs.
Provention Bio, Inc. (Nasdaq: PRVB) has launched the #Type1TestedPledge campaign during Diabetes Awareness Month to enhance awareness of type 1 diabetes (T1D) risk factors and the significance of early screening. T1D affects 1.6 million Americans, with many cases going undetected. The campaign aims to encourage the community to partake in discussions about T1D and promote screening among those with a family history. Provention Bio highlights that early detection can prevent severe complications associated with T1D.
Provention Bio, Inc. (Nasdaq: PRVB) has appointed Miguel Sanjuan, Ph.D., as Senior Vice President of Research and Early Development, enhancing expertise in immunomodulatory therapy and autoimmune diseases. Dr. Sanjuan, who boasts over 20 years of experience, previously held positions at Gossamer Bio and Bristol Myers Squibb. The company granted him an inducement stock option of 175,000 shares with an exercise price of $6.54. This strategic hire aims to bolster Provention's pipeline of therapies designed to intercept autoimmune diseases as the company seeks to expand its impact.
Provention Bio, Inc. (Nasdaq: PRVB) announced the appointment of Thierry Chauche as the new Chief Financial Officer, effective December 1, 2021. He succeeds Andrew Drechsler, who will retire after nearly 30 years in finance and life sciences, though he will remain as a special advisor until mid-2022. Chauche brings over two decades of financial experience from companies like Alexion Pharmaceuticals and Novartis. CEO Ashleigh Palmer expressed gratitude to Drechsler for his contributions and confidence in Chauche's ability to drive the company's next phase of growth aimed at autoimmune disease therapies.
Provention Bio, Inc. (Nasdaq: PRVB) reported its Q3 2021 results, showing a net loss of $27 million or $0.43 per share, an improvement from $31.3 million or $0.56 per share in Q3 2020. The company achieved target enrollment of 300 patients in the Phase 3 PROTECT trial for teplizumab. However, a Complete Response Letter from the FDA for teplizumab remains a concern. Positive interim results for the coxsackievirus B vaccine candidate, PRV-101, were announced, and the company expects to initiate a Phase 2a trial for PRV-3279 in Q4 2021.
Provention Bio, Inc. (Nasdaq: PRVB) will release its third quarter 2021 financial results on November 4, 2021, before the U.S. markets open. Following this, a conference call is scheduled for 8:00 am E.T. to discuss the results and provide corporate updates. The company focuses on investigational therapies for immune-mediated diseases, including type 1 diabetes and celiac disease. For call access, dial 1-888-347-7861 or join via their website for an audio webcast. More information is available at www.proventionbio.com.
Provention Bio, Inc. (Nasdaq: PRVB) announced positive interim results from the PROVENT trial of PRV-101, a coxsackievirus B vaccine candidate aimed at preventing type 1 diabetes (T1D) and celiac disease. The Phase 1 study showed PRV-101 was well tolerated with no serious adverse events, while successfully inducing high levels of viral-neutralizing antibodies in participants. This vaccine, licensed from Vactech Oy, is designed to block CVB infections and potentially reduce the risk of autoimmune diseases in genetically susceptible individuals. Final results are expected in 2022.
Provention Bio, Inc. (Nasdaq: PRVB) announced participation in the Cantor Fitzgerald Virtual Global Healthcare Conference 2021 on September 29, 2021, at 3:20 PM E.T. The event will be accessible via live webcast on the company's website and archived for 30 days post-presentation. Provention Bio focuses on developing therapies to intercept and prevent immune-mediated diseases such as type 1 diabetes and lupus. For more details, visit www.ProventionBio.com.
Provention Bio, Inc. (Nasdaq: PRVB) announced its participation in a fireside chat at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 22, 2021, at 9:05 AM E.T. The event will be webcast live and available for 30 days on the company's website. Provention Bio is committed to developing therapies to intercept and prevent immune-mediated diseases, with a pipeline targeting autoimmune conditions like type 1 diabetes and lupus. For more updates, visit www.ProventionBio.com.
Provention Bio, Inc. (Nasdaq: PRVB) has provided an update regarding its ongoing efforts to address FDA concerns outlined in the Complete Response Letter received on July 2, 2021, regarding teplizumab for Type 1 Diabetes (T1D). The company has completed data collection from a Phase 3 substudy and is planning to request a formal Type A meeting with the FDA to finalize the population pharmacokinetic (PK) model design. Preliminary data from the substudy shows supportive pharmacodynamic (PD) markers, though the FDA has yet to assess their significance. The company believes it has addressed or can quickly resolve product quality issues noted in the CRL.
